IV Compatibility of Ofirmev and Folic Acid
Ofirmev (IV acetaminophen) and intravenous folic acid should NOT be administered simultaneously through the same IV line, as there is no established compatibility data for this specific drug combination.
Evidence-Based Recommendation
The FDA-approved drug label for Ofirmev explicitly states that "Do not add other medications to the OFIRMEV vial or infusion device" and "Do not add other medications to the OFIRMEV solution" 1. This is a critical safety directive that applies to all medications not specifically tested for compatibility.
Documented Incompatibilities
Known incompatible medications with Ofirmev include:
- Diazepam - physically incompatible, must not be administered simultaneously 1
- Chlorpromazine hydrochloride - physically incompatible, must not be administered simultaneously 1
- Acyclovir - demonstrated incompatibility in Y-site testing 2
Tested Compatible Medications
A comprehensive Y-site compatibility study evaluated Ofirmev with 22 commonly used IV medications over 4 hours 2. Folic acid was NOT included in this compatibility testing, which represents a significant evidence gap. The study confirmed both physical and chemical compatibility only with: ceftriaxone, diphenhydramine, granisetron, ketorolac, nalbuphine, ondansetron, piperacillin/tazobactam, and vancomycin 2.
Clinical Management Strategy
To safely administer both medications:
- Use separate IV access sites - This is the safest approach when compatibility data is unavailable 1
- Flush the line thoroughly - If separate access is unavailable, complete the Ofirmev infusion, flush the line with compatible solution, then administer folic acid
- Administer sequentially, not simultaneously - Never mix these medications in the same container or infuse concurrently through a Y-site 1
Administration Specifications
For Ofirmev:
- Must be administered over 15 minutes 1
- Once container seal is penetrated, use within 6 hours 1
- Examine for particulate matter or discoloration before administration 1
For folic acid:
- Can be administered intramuscularly or intravenously 3
- Bioavailability is comparable between IM and IV routes 3
Critical Safety Considerations
The absence of compatibility data does not prove incompatibility, but clinical practice must err on the side of caution when patient safety is at stake. The potential for physical incompatibility (precipitation, color change, particle formation) or chemical degradation exists with any untested drug combination 2, 4.
Common pitfalls to avoid:
- Assuming compatibility based on individual drug stability alone
- Mixing medications in syringes or bags without documented compatibility data
- Failing to visually inspect solutions before and during administration 1, 2
The pharmaceutical principle that guides this recommendation is clear: without specific compatibility testing under clinically relevant conditions (temperature, concentration, duration), co-administration cannot be considered safe 2, 4.